Tuesday, 25 Jul 2017

You are here

Treat-to-Target in Spondyloarthropathies

Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.

Similar to how diabetes control and outcomes improved with introduction of treat to target concept in endocrinology, rheumatologists are looking to adopt similar strategies for more effective management of rheumatic disease outcomes.

In his presentation today Dr. Braun raised two important questions:

  1. what is the target in treatment of rheumatic diseases? and

  2. is T2T applicable in SpA?

While more easily defined in rheumatoid arthritis, remission is a more complicated target in SpA with axial involvement. The majority of published studies conclude that overall mortality and morbidity in SpA is linked to disease activity. Longitudinal relationship as observed between disease activity and radiographic damage over time:

Existent treatment guidelines are helpful in achieving treatment. When used in T2T approach, ASDAS showed to be effective outcome measure in axSpA comparable to DAS in RA.

 

Dr. Braun concluded that T2T can be effectively used in SpA and patients would benefit if rheumatologists follow this concept.

Add new comment

More Like This

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

The RheumNow Week in Review – 30 June 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.